References
- Caroff S. N. The Neuroleptic Malignant Syndrome. Journal of Clinical Psychiatry 1980; 41: 79–83
- Levenson J. L. Neuroleptic Malignant Syndrome. American Journal of Psychiatry 1985; 142: 1137–1145
- Addonizio G., Susman V. L., Roth S. D. Neuroleptic Malignant Syndrome: review and analysis of 115 cases. Biological Psychiatry 1987; 22: 1004–1020
- Shalev A., Mermesh H., Munitz H. Mortality from Neuroleptic Malignant Syndrome. Journal of Clinical Psychiatry 1989; 50: 18–25
- Keck P. E., Pope H. G., Cohen B. M., McElroy S. L., Nierenberg A. A. Risk factors for Neuroleptic Malignant Syndrome: A case-control study. Archives of General Psychiatry 1989; 46: 914–918
- Aditanjee A. The myth of elevated serum creatine phosphokinase level and Neuroleptic Malignant Syndrome. British Journal of Psychiatry 1990; 158: 706–707
- Craddock B., Craddock N., Milner G. CPK in NMS. British Journal of Psychiatry 1991; 158: 130–138
- McItzer H. Y., Ross-Stanton J., Schlessinger S. Mean serum creatine kinase activity in patients with functional psychoses. Archives of General Psychiatry 1980; 37: 650–655
- Black H. R., Quallich H., Gareleck C. B. Racial differences in serum creatine kinase levels. American Journal of Medicine 1985; 81: 479–487
- Gabow P., Kachny W. D., Kelleher S. P. The spectrum of rhabdomyolsis. Medicine 1982; 61: 141–149
- Meltzer H. Y., Nankin R., Raftery J. Serum creatine phosphokinase activity in newly admitted psychiatric patients. Archives of General Psychiatry 1971; 24: 568–572
- Pearlman C., Wheadon D., Epstein S. Creatine kinase elevation after neuroleptic treatment. American Journal of Psychiatry 1988; 145: 1018–1019